DeepWell Therapeutics is a clinical-stage biotech company focused on novel therapies for neurological and psychiatric disorders, including depression, anxiety, and post-traumatic stress disorder (PTSD). Its lead candidate is a proprietary oral psychedelic compound designed to provide rapid, sustained relief from treatment-resistant depression with reduced side effects compared to traditional antidepressants.
The company’s drug discovery platform targets the brain’s serotonin receptors, modulating neural pathways associated with mood and cognition. DeepWell’s compounds are being evaluated in Phase II trials for depression and PTSD, with preliminary data showing significant improvements in patient symptoms within days of administration. It also has preclinical programs in neurodegenerative diseases such as Alzheimer’s.
Raising $350 million in its IPO, DeepWell plans to accelerate clinical trials, expand its pipeline, and build commercial capabilities. While pre-revenue with a $72 million net loss in 2025, the company’s focus on underserved mental health conditions and rapid-acting therapies has attracted significant investor attention.